Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34, (Summary Text)
- Publication Type: Conference Paper / Summary Text
- Volume: 34
- Doi Number: 10.1200/jco.2016.34.15_suppl.7525
- City: Illinois
- Country: United States Of America
- Dokuz Eylül University Affiliated: Yes